FDA import alert halts Shengnuo Biotech's US peptide API shipments, stock plunges 18.61%
On September 22, 2026, Shengnuo Biotech announced its subsidiary, Chengdu Shengnuo Biopharmaceutical, was placed on the FDA's Import Alert 66-40 list on September 19, 2026, following an August inspection that found eight deficiencies. The company has suspended all US peptide API sales and shipments. The US market accounted for 32.83% of Shengnuo's H1 2026 revenue. The stock fell 18.61% on the announcement.
Reference imageEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Reporting timeline
Shengnuo Biotech subsidiary placed on FDA import alert, halting US peptide API shipments
On September 22, Shengnuo Biotech announced that its wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical, was placed on the FDA's import alert 66-40 list following an on-site inspection in August 2026. The inspection, conducted from August 20-22, 24, and 27, resulted in a Form FDA 483 with eight deficiencies related to quality attribute identification, contamination control, test result acceptance, and quality system governance. Until the alert is lifted, the subsidiary has fully suspended sales and shipment of peptide active pharmaceutical ingredients (APIs) to the US market. The US market accounted for 32.83% of Shengnuo's total revenue in the first half of 2026, making this a significant financial blow. The company has submitted an initial response and corrective plan to the FDA and is working on remediation. The stock price fell 18.61% on the day of the announcement, hitting a new yearly low. Market attention is focused on the timeline for lifting the alert and potential loss of US customer orders.
Read sourceShengnuo Biotech shares flash crash after FDA import ban, revenue outlook dims
Shengnuo Biotech (688117) saw its stock price plunge 18.61% on September 22, hitting a new 2026 low, after disclosing that its subsidiary Shengnuo Pharmaceutical received a Form FDA 483 with eight observations following an FDA inspection in August 2026. The FDA subsequently placed the subsidiary on Import Alert 66-40 on September 19, 2026. The observations relate to critical quality attribute identification, contamination control, detection and result reliability, and quality system governance for a group of products. Shengnuo has submitted an initial response and corrective actions but has not yet received a warning letter or official action from the FDA. The company has committed to halting all sales and shipments of peptide APIs to the US market until the alert is lifted. The US market accounted for 32.83% of Shengnuo's revenue in the first half of 2026, up from 20.19% in 2025, making the ban a significant risk to future earnings.
Read sourceShengnuo Biological Subsidiary Placed on FDA Import Ban List After Inspection Findings
Chengdu Shengnuo Biological Technology Co., Ltd. announced that its wholly-owned subsidiary, Chengdu Shengnuo Biological Pharmaceutical Co., Ltd. (Shengnuo Pharmaceutical), was placed on the FDA's 66-40 import ban list on September 19, 2026. The action follows an FDA inspection conducted from August 20-27, 2026, which resulted in a Form FDA 483 with 8 observations related to critical quality attribute identification, contamination control, detection and result reliability, and quality system governance. Shengnuo submitted an initial response and corrective measures to the FDA on September 17, 2026. The company stated it has not yet received an Official Action Indicated (OAI) conclusion or a Warning Letter from the FDA. In 2025, Shengnuo's US sales were 153.4 million yuan (20.19% of revenue); in the first half of 2026, US sales rose to 166.6 million yuan (32.83% of revenue). The company has committed to halting all US sales and shipments of peptide raw materials from the subsidiary until the ban is lifted, and is pursuing remediation and FDA re-inspection.
Read sourceShow 4 older updatesHide older updates
ShengNuo Biotech subsidiary placed on FDA import ban list, may hurt earnings
ShengNuo Biotech (圣诺生物) announced in a midday filing on September 22 that its wholly-owned subsidiary, ShengNuo Pharmaceutical (圣诺制药), was inspected by the U.S. Food and Drug Administration (FDA) in August 2026. The FDA issued a Form FDA 483 with eight observations on August 27. The company submitted an initial response and corrective actions. As of September 19, 2026, the subsidiary was placed on the FDA's Import Alert 66-40 list, though the company has not yet received an official action letter or a warning letter. ShengNuo Biotech reported US sales of 167 million yuan in the first half of 2026, accounting for 32.83% of total revenue. The company warned that this development may have a certain adverse impact on its operating performance and pledged to halt all sales and shipments of peptide active pharmaceutical ingredients to the US market until the FDA alert is lifted.
Read sourceShengnuo Biotech Subsidiary Placed on FDA Import Ban List, May Hit Earnings
Shengnuo Biotech announced that its wholly-owned subsidiary, Shengnuo Pharmaceutical, was placed on the U.S. Food and Drug Administration's (FDA) 66-40 import ban list on September 19, 2026, following an FDA inspection in August 2026. The inspection resulted in a Form FDA 483 observation list citing 8 items. The company has submitted an initial response and corrective actions to the FDA but has not yet received an official action letter or a warning letter. In the first half of 2026, Shengnuo generated 167 million yuan in U.S. sales, accounting for 32.83% of its total revenue. The company stated that the incident may have a certain adverse impact on its operating performance and has committed to fully suspending all sales and shipments of peptide active pharmaceutical ingredients (APIs) to the U.S. market until the FDA-related warning is lifted.
Read sourceShengnuo Biotech subsidiary Shengnuo Pharma placed on FDA import ban list
Shengnuo Biotech (688117.SH) announced that its wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd. (Shengnuo Pharma), underwent an on-site inspection by the U.S. Food and Drug Administration (FDA) from August 20-22, August 24, and August 27, 2026. On August 27, the FDA issued a Form FDA 483 observation report citing 8 observations related to critical quality attribute identification, contamination control, detection and result reliability, and quality system governance for the same product group and production/packaging process. The company submitted an initial response and corrective measures via email to the FDA's CDER Office of Manufacturing Quality on September 17, 2026. As of now, Shengnuo Pharma has been listed on the FDA's Import Alert 66-40 as of September 19, 2026. However, the company has not yet received an Official Action Indicated (OAI) conclusion or a Warning Letter from the FDA beyond the Form FDA 483.
Shengnuo Biotech Subsidiary Placed on FDA Import Ban List, May Hit Earnings
Shengnuo Biotech (688117) announced on September 22 that its wholly-owned subsidiary, Shengnuo Pharmaceutical, was inspected by the U.S. Food and Drug Administration (FDA) in August 2026. The FDA issued a Form FDA 483 observation sheet citing 8 observations. The company submitted an initial response and corrective actions. As of September 19, 2026, the subsidiary was placed on the FDA's 66-40 import ban list, though no official action letter or warning letter has been received. The company's U.S. sales revenue for the first half of 2026 was 1.67 billion yuan, accounting for 32.83% of total revenue. The company stated this may have a certain adverse impact on performance and has committed to fully suspending all peptide API sales and shipments to the U.S. market until the FDA warning is lifted.
Read source